Golus, M.; Bugajski, P.; Chorbińska, J.; Krajewski, W.; Lemiński, A.; Saczko, J.; Kulbacka, J.; Szydełko, T.; Małkiewicz, B. STAT3 and Its Pathways’ Dysregulation—Underestimated Role in Urological Tumors. Cells2022, 11, 3024.
Golus, M.; Bugajski, P.; Chorbińska, J.; Krajewski, W.; Lemiński, A.; Saczko, J.; Kulbacka, J.; Szydełko, T.; Małkiewicz, B. STAT3 and Its Pathways’ Dysregulation—Underestimated Role in Urological Tumors. Cells 2022, 11, 3024.
Nowadays molecular research is essential for the better understanding of tumor cells pathophysiology. The increasing number of neoplasms is taken under ‘the molecular magnifying glass’ therefore it is possible to discover complex relationships between cytophysiology and tumor cells. Signal transducer and activator of transcription 3 (STAT3) belongs to the family of latent cytoplasmic transcription factors called STATs which comprises seven members: STAT1, STAT2, STAT3, STAT5A, STAT5B, STAT6. Those proteins play important role in cytokine-activated gene expression by transducing signals from the cell membrane to the nucleus. Abnormal prolonged activation results in tumorigenesis, metastasis, cell proliferation, invasion, migration and angiogenesis. Inhibition of this transcription factor inhibits previously mentioned effects in cancer cells whereas normal cells are not affected. Hence STAT3 might be a viable target for cancer therapy.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.